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Abstract
Background: HTLV-1 infection is a neglected disease, despite infecting 10–15 million people worldwide and
severe illnesses develop in 10% of carriers lifelong. Acknowledging a greater risk for developing HTLV-1
associated illnesses due to immunosuppression, screening is being widely considered in the transplantation
setting. Herein, we report the experience with universal HTLV testing of donors and recipients of solid organ
transplants in a survey conducted in Spain.
Methods: All hospitals belonging to the Spanish HTLV network were invited to participate in the study. Briefly, HTLV
antibody screening was performed retrospectively in all specimens collected from solid organ donors and recipients
attended since the year 2008.
Results: A total of 5751 individuals were tested for HTLV antibodies at 8 sites. Donors represented 2312
(42.2%), of whom 17 (0.3%) were living kidney donors. The remaining 3439 (59.8%) were recipients. Spaniards
represented nearly 80%.
Overall, 9 individuals (0.16%) were initially reactive for HTLV antibodies. Six were donors and 3 were recipients.
Using confirmatory tests, HTLV-1 could be confirmed in only two donors, one Spaniard and another from
Colombia. Both kidneys of the Spaniard were inadvertently transplanted. Subacute myelopathy developed
within 1 year in one recipient. The second recipient seroconverted for HTLV-1 but the kidney had to be
removed soon due to rejection. Immunosuppression was stopped and 3 years later the patient remains in
dialysis but otherwise asymptomatic.
Conclusion: The rate of HTLV-1 is low but not negligible in donors/recipients of solid organ transplants in
Spain. Universal HTLV screening should be recommended in all donor and recipients of solid organ
transplantation in Spain. Evidence is overwhelming for very high virus transmission and increased risk along
with the rapid development of subacute myelopathy.
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Background
HTLV-1 infection is a neglected disease. As with other
human retroviruses, i.e. HIV, acute infection is universally
followed by long-lasting persistence of the virus. Clinical
manifestations develop in roughly 10% of carriers lifelong,
typically as subacute myelopathy which is known as trop-
ical spastic paraparesis/HTLV-1-associated myelopathy
(TSP/HAM) [1] or a lymphoproliferative disorder named
adult T-cell leukaemia/lymphoma (ATLL) [2]. Screening
for HTLV antibodies is recommended in blood donors in
some countries. Acknowledging a greater risk for develop-
ing HTLV-1 associated illnesses due to immunosuppres-
sion [3], screening of transplant donors and recipients is
widely being encouraged [4].
Spain is leading solid organ transplantation worldwide.
With 47 million people, 5261 transplants were per-
formed in 2017 (kidney 3269), liver (1247), lung (363)
and heart (304). Overall it represents 20% of transplants
within the European Union. Until recently, the Spanish
law only recommended HTLV testing for persons with
high epidemiological risk of infection [5]. Herein, we
report the experience with universal testing of a large
population of donors and recipients of solid organ trans-
plants in Spain.
Method
A nationwide network of hospitals/clinics/labs was set up
in Spain in 1989 and a national register of HTLV-1 cases
works since then. Currently, more than 50 centres distrib-
uted across the Spanish geography belong to this group.
Further information on this network has been reported
elsewhere [6]. All hospitals were invited to participate in
the current study. Briefly, HTLV antibody screening using
chemiluminescence and/or ELISA of all solid organ
donors and recipients attended since 2008 was retrospect-
ively analyzed.
Statistical analysis
All numerical variables are reported as absolute values
and percentages. Categorical variables were compared
using χ2 or Fisher exact tests whereas non-categorical
variables were compared using Student T-test or Mann-
Whitney U tests. All analyses were 2-tailed and only p
values below 0.05 were considered as significant. All
statistical analyses were performed using SPSS software
version 16.0 (SPSS Inc., Chicago, IL).
Results
A total of 5751 individuals were tested for HTLV anti-
bodies at 8 sites. Table 1 records the main characteris-
tics of the study population. Donors represented 2312
(42.2%), of whom only 17 (0.3%) were living kidney do-
nors. The remaining 3439 (59.8%) were recipients.
Males were predominant (59.7%). The median age was
57-years old. Spaniards represented nearly 80%, being
Latin Americans only 65 (1.1%) and Africans 101
(1.8%). Overall, transplant recipients were more fre-
quently male, younger, and native Spaniards than organ
donors.
Overall, 9 individuals were initially reactive for HTLV
antibodies. Table 2 summarizes the main characteristics
of these patients. Six were donors and 3 were recipients.
Using confirmatory tests (western blot and PCR),
HTLV-1 was found in only two patients. Another three
were positive for HTLV-2. Two samples gave indeter-
minate results and another two were negative.
The two HTLV-1 positive cases were donors. Thus,
the overall rate of HTLV-1 among solid transplant do-
nors in our study was 0.09%. The first individual was a
49-year old female, born in Colombia, diagnosed in
2015, at the time she was assessed to be a kidney living
donor. Before moving to the surgical procedure, she was
discharged as potential donor following knowledge of
her HTLV-1 seropositive status.
Table 1 Main features of the study population
Total Donors Recipients p
No. (%) 5751 2312 (42.2%)a 3439 (59.8%) –
Male gender (%) 3435 (59.7) 1234 (53.4) 2201 (64) < 0.001
Median age (IQR, years) 57 (45–66) 59 (45–71) 56 (45–65) < 0.001
Country of birth (%)
Spain 4595 (79.9) 1383 (59.8) 3212 (93.4) < 0.001
Other EU countries 114 (2) 34 (1.5) 80 (2.3) –
Africa 101 (1.8) 14 (0.6) 87 (2.5) < 0.05
Latin America 65 (1.1) 25 (1.1) 40 (1.2) –
Asia 9 (0.2) 4 (0.2) 5 (0.1) –
Unknown 867 (15.1) 851 (36.8) 15 (0.4) –
a17 (0.3%) donors were living kidney donors
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The second HTLV-1 case was a 38-year old male, born
in Spain, that died in 2015. Both kidneys were inadvert-
ently transplanted. TSP/HAM developed within 1 year
in one recipient, despite antiretroviral prophylaxis
attempted within the first weeks. The second recipient
seroconverted for HTLV-1 but the kidney had to be
removed soon due to rejection. Immunosuppression was
stopped and to date, 3 years later, the patient remains in
dialysis but otherwise asymptomatic.
The three HTLV-2 cases were two donors and one
recipient. All had been born in Spain. The last patient
died before transplantation. The two donors were finally
discharged from transplantation because they were also
positive for HIV and hepatitis C.
Discussion
More than 35 years after the discovery of HTLV-1 [7],
donor/recipient screening for the virus remains sporadic
or non-existent in most countries. In 1993, the American
CDC recommended that persons infected with HTLV be
counselled “not to donate blood, semen, body organs or
other tissues” [8]. Nevertheless, in the year 2009 the rec-
ommendation for universal HTLV screening in deceased
organ donors was dropped in the United States because of
the perception of low HTLV-1 prevalence and low positive
predictive value of serologic screening tests [9]. Alongside
this recommendation, most international transplant soci-
ety guidelines currently do not provide any advice on
HTLV-1 screening and use of donated organs.
High rates of HTLV-1 have been found in specific
groups in non-endemic regions of North America [10]
and Europe [11], and decades of migration/immigration
and tourism/travelling have altered the demographics of
many Western countries. For example, the ongoing
refugee migration from the Middle East and Africa
would rapidly change the prevalence of HTLV-1 in many
European countries. For a while this has been the case
with Latin Americans in Spain, given the large flux of
immigration facilitated by strong cultural and ancestor
links [6].
Since the year 1988 there is a national register of
HTLV-1 cases in Spain. A total of 369 cases had been re-
ported until December 2018. Most cases are concen-
trated around the largest urban areas (Madrid and
Barcelona) where the greatest immigrant populations are
living. However, HTLV-1-infected persons have been
identified across the whole Spanish geography. Although
many were immigrants from endemic areas, mostly in
Latin America, up to 18% were native Spaniards [6].
The rapid development of subacute myelopathy was
seen in one of our recipients from a kidney from the
HTLV-1 positive cadaveric donor. Similar cases of sub-
acute myelopathy shortly after transplantation have
already been reported in the literature [12–14], including
a series of recipients from a single donor in Spain [15].
Myelopathy was originally reported in a heart transplant
recipient in France following HTLV-1 acquisition from
contaminated blood transfusions during the surgery
[16]. Transplant immunosuppression seems to play a
major role in the accelerated disease progression in this
setting [17].
In response to the worldwide evolving foci of HTLV-1
infections and the very poor prognosis of post-transplant
virus-associated illnesses, there are urgent calls for a
broader HTLV-1 screening of live and -more difficult- de-
ceased organ donors. Organ procurement organizations
and transplant programs should determine local preva-
lence to guide HTLV-1 screening efforts [10]. Targeted
screening of potential high-risk living (and deceased) do-
nors for HTLV-1 has been recommended by some authors
[13]. Suggestions also have been put forward for national
or international registries of all HTLV-1-affected trans-
plants [17]. Alerted to the dangers of rapid-onset TSP
following HTLV-1-infected organ transplants, Japan began
in 2014 screening for HTLV-1 of all kidney donations.
Similarly, the United Kingdom issued new transplantation
guidance on HTLV-1 screening of cadaveric solid organs
Table 2 Main features of HTLV-seroreactive individuals
Case Year Donor or Recipient Gender Age range (years) Country of birth Confirmatory test
1 2010 donor female 35–40 Spain HTLV-2
2 2011 donor female 80–85 Spain negative
3 2011 recipient male 45–50 Spain indeterminate
4 2011 donor male 45–50 Spain HTLV-2
5 2015 donor male 35–40 Spain HTLV-1
6 2015 donor female 45–50 Colombia HTLV-1
7 2015 recipient male 45–50 Spain HTLV-2
8 2016 donor male 50–55 Spain negative
9 2017 recipient female 25–30 Colombia indeterminate
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in 2011. Finally, the Global Virus Network has recently
called for more systematic HTLV-1 screening before solid
organ transplantation everywhere [4].
The screening costs for HTLV-1 are small in compari-
son with the cost of post-transplant illnesses and/or
death associated with TSP or ATL following HTLV-1
infection [18]. For all these reasons, the American and
European CDCs along with other health prevention
agencies should urgently update their policy recommen-
dations on organ transplant HTLV-1 screening. In the
meantime, some transplant centres around the world,
including a few in Spain, have already implemented
“rapid” (or “urgent”) HTLV-1 testing of all deceased
organ donors. In parallel, diagnostic companies should
design rapid tools (i.e., point-of-care (PIC) assays) and
improve the specificity of HTLV-1 screening tests to
minimize unwanted organ discharge.
Our findings call into question the current view that
anti-HTLV screening of donated organs is not needed or
just recommended when there is suspicion, as it is
recommended in Spain [5]. This opinion is based on the
assumption that HTLV-1-associated diseases will
develop only in a small proportion of carriers and that
progression to disease is slow compared with the average
lifespan of humans and therefore poses no major threats
to public health. In the transplant setting, the very high
risk of transmission and the high rate along with short-
term for developing HTLV-1 disease most likely results
from immunosuppressive therapy.
Conclusion
We report a low but not negligible rate of HTLV-1 infec-
tion among donors and recipients of solid organ trans-
plants in Spain. Of note, unaware HTLV-1-infected
donors were not exclusively foreigners from highly
endemic areas but native Spaniards that most likely have
been exposed to HTLV-1 by sexual contact. Therefore,
universal HTLV screening should be recommended in all
donor and recipients of solid organ transplantation in
Spain. Evidence is overwhelming for very high -if not uni-
form- virus transmission and increased risk as well as
rapid disease progression, mostly subacute myelopathy.
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